B · Normal
[Longshenrongfa: The drug marketing application of its holding subsidiary was not approved] On September 17, Longshenrongfa (300534.SZ) announced that its holding subsidiary Pu'an Pharmaceutical received the "Notice of Disapproval of Drug Marketing Application" issued by the State Food and Drug Administration. Its application for marketing of bripiprazole orally dissolving film did not meet the relevant requirements for drug registration and was not approved. This drug can be used to treat schizophrenia. It was not approved this time because the pharmaceutical registration verification conclusion failed. The company stated that this matter will not have a significant impact on the current performance.
Comments